Beaudin Stephane A, Howard Shanna, Santiago Nicholas, Strupp Barbara J, Smith Donald R
Department of Microbiology and Environmental Toxicology, University of California, Santa Cruz, Santa Cruz, California, USA.
Division of Nutritional Sciences, and Department of Psychology, Cornell University, Ithaca, New York, USA.
bioRxiv. 2023 Oct 4:2023.06.27.546786. doi: 10.1101/2023.06.27.546786.
Environmental manganese (Mn) exposure is associated with impaired attention and psychomotor functioning, as well as impulsivity/hyperactivity in children and adolescents. We have shown previously that developmental Mn exposure can cause these same dysfunctions in a rat model. Methylphenidate (MPH) lessens impairments in attention, impulse control, and sensorimotor function in children, but it is unknown whether MPH ameliorates these dysfunctions when induced by developmental Mn exposure. Here, we sought to (1) determine whether oral MPH treatment ameliorates the lasting attention and sensorimotor impairments caused by developmental Mn exposure, and (2) elucidate the mechanism(s) of Mn neurotoxicity and MPH effectiveness. Rats were given 50 mg Mn/kg/d orally over PND 1-21 and assessed as adults in a series of attention, impulse control and sensorimotor tasks during oral MPH treatment (0, 0.5, 1.5, or 3.0 mg/kg/d). Subsequently, selective catecholaminergic receptor antagonists were administered to gain insight into the mechanism(s) of action of Mn and MPH. Developmental Mn exposure caused persistent attention and sensorimotor impairments. MPH treatment at 0.5 mg/kg/d completely ameliorated the Mn attentional dysfunction, whereas the sensorimotor deficits were ameliorated by the 3.0 mg/kg/d MPH dose. Notably, the MPH benefit on attention was only apparent after prolonged treatment, while MPH efficacy for the sensorimotor deficits emerged early in treatment. Selectively antagonizing D1, D2, or α2 receptors had no effect on the Mn-induced attentional dysfunction or MPH efficacy in this domain. However, antagonism of D2R attenuated the Mn sensorimotor deficits, whereas the efficacy of MPH to ameliorate those deficits was diminished by D1R antagonism. These findings demonstrate that MPH is effective in alleviating the lasting attention and sensorimotor dysfunction caused by developmental Mn exposure, and they clarify the mechanisms underlying developmental Mn neurotoxicity and MPH efficacy. Given that the cause of attention and psychomotor deficits in children is often unknown, these findings have implications for the treatment of environmentally-induced attentional and psychomotor dysfunction in children more broadly.
环境锰(Mn)暴露与儿童和青少年的注意力受损、精神运动功能障碍以及冲动/多动有关。我们之前已经表明,发育过程中锰暴露会在大鼠模型中导致这些相同的功能障碍。哌甲酯(MPH)可减轻儿童的注意力、冲动控制和感觉运动功能的损害,但尚不清楚MPH是否能改善发育性锰暴露引起的这些功能障碍。在这里,我们试图(1)确定口服MPH治疗是否能改善发育性锰暴露引起的持续注意力和感觉运动障碍,以及(2)阐明锰神经毒性和MPH有效性的机制。在出生后第1 - 21天,给大鼠口服50 mg Mn/kg/d,并在口服MPH治疗(0、0.5、1.5或3.0 mg/kg/d)期间作为成年大鼠进行一系列注意力、冲动控制和感觉运动任务评估。随后,给予选择性儿茶酚胺能受体拮抗剂,以深入了解锰和MPH的作用机制。发育性锰暴露导致持续的注意力和感觉运动障碍。0.5 mg/kg/d的MPH治疗完全改善了锰引起的注意力功能障碍,而3.0 mg/kg/d的MPH剂量改善了感觉运动缺陷。值得注意的是,MPH对注意力的益处仅在长期治疗后才明显,而MPH对感觉运动缺陷的疗效在治疗早期就出现了。选择性拮抗D1、D2或α2受体对锰诱导的注意力功能障碍或该领域的MPH疗效没有影响。然而,拮抗D2R可减轻锰的感觉运动缺陷,而拮抗D1R则降低了MPH改善这些缺陷的疗效。这些发现表明,MPH可有效减轻发育性锰暴露引起的持续注意力和感觉运动功能障碍,并阐明了发育性锰神经毒性和MPH疗效的潜在机制。鉴于儿童注意力和精神运动缺陷的原因往往不明,这些发现对更广泛地治疗儿童环境诱导的注意力和精神运动功能障碍具有启示意义。